tirzepatide clinicaltrials gov Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial #Tirzepatide vs. #Semaglutide: Key Weight
Pay in 4 interest-free payments of $5.55 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18


























